NIH Reporter #5R35GM156770-02

Development of Non-covalent Antibody Drug Complexes (ADCx) for Targeted Drug Delivery

This opportunity involves the National Institute of General Medical Sciences (NIGMS) funding a research project at the University of Michigan at Ann Arbor to advance targeted drug delivery technologies. - Government Buyer: - National Institute of General Medical Sciences (NIGMS), University of Michigan at Ann Arbor - Project Scope: - Development of a non-covalent antibody drug delivery platform (ADCx) - Creation and optimization of anti-drug antibodies for targeted delivery - Comparative studies in mice between lead anti-MMAE anti-HER2 ADCx and trastuzumab-vc-MMAE ADC - Products/Services Requested: - Research and development services for ADCx platform - Pharmacokinetic, efficacy, and tolerability studies - OEMs and Vendors: - No specific OEMs or commercial vendors named - References to antibody drugs: trastuzumab-vc-MMAE, anti-MMAE anti-HER2 ADCx - Unique Requirements: - Focus on maximizing tolerability and efficacy of ADCx - Potential applications in cancer, autoimmunity, and infectious diseases - Estimated Award Value: - $390,000

Description

This project involves the development of a non-covalent antibody-based drug delivery strategy called ADCx, which aims to bypass the linker payload conjugation step required in traditional antibody-drug conjugates. The research will compare a lead anti-MMAE anti-HER2 ADCx to trastuzumab-vc-MMAE ADC in pharmacokinetic, efficacy, and tolerability studies in mice. The goal is to optimize antibody and drug attributes to maximize ADCx tolerability and efficacy, potentially treating conditions such as cancer, autoimmunity, and infectious diseases. Objectives include developing ADCx as a versatile drug delivery platform, discovering additional anti-drug antibodies, and optimizing lead antibodies for developability.

View original listing